• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Test Strip Detects Both Fentanyl & Xylazine Launches in Delaware to Combat Opioid Deaths

by Syed Hamza Sohail 07/24/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

  • SIVAD Diagnostic Medical Group LLC (SIVAD), a minority-owned company dedicated to addressing the unique needs of underserved and unserved communities in the United States and globally, recently announced the launch of HarmGuard FX in Delaware, the first state in the nation to distribute this groundbreaking approach to reducing overdose deaths.
  • HarmGuard FX is a single, low-cost strip that provides an affordable, reliable way for people to test substances for fentanyl and xylazine (popularly known as tranq), two dangerous adulterants that are exacerbating the already critical opioid epidemic.

Tackling the Opioid Epidemic with Affordable Testing

The U.S. Drug Enforcement Administration (DEA) recently reported that it had found the deadly combination of fentanyl and xylazine in nearly a quarter of drugs sampled from 48 out of 50 states.1 According to the Centers for Disease Control and Prevention (CDC), between 2018 and 2021, deaths involving xylazine increased by 1,238%, leading the White House Office of National Drug Control Policy to designate fentanyl combined with xylazine as an emerging threat to the U.S.2

“As a company committed to leveraging technology to democratize health care and address the needs of underserved and marginalized communities, SIVAD developed our Harm Stopper™ Program to provide comprehensive resources that can reduce the harm of fentanyl and xylazine for substance users, the community advocates who support them, health professionals, and law enforcement personnel,” said Jermonica Boardley, CEO and President at SIVAD, who is leading the Harm Stopper Program. “We commend Lt. Governor Bethany Hall-Long for making Delaware the first state to pilot HarmGuard FX and are collaborating with Delaware health officials spearheaded by Susan Holloway to implement a pilot program that could serve as a blueprint for other states seeking to prevent overdose deaths. As other states receive and deploy funds from the National Opioids Settlement, we hope to work with them to implement HarmGuard FX and our Harm Stopper Portal as part of their harm-reduction strategies.” 

SIVAD’s Harm Stopper Program includes the HarmGuard FX test strip and the Harm Stopper Portal. The comprehensive, cloud-based, AI-driven portal provides education, resources, and information at the national level, and for participating states, uses advanced geolocation to provide the user with instant access to local resources and information related to harm reduction. Using the QR code on each HarmGuard FX package, people can quickly find local, free naloxone distribution locations, needle exchange programs, counseling, emergency services, and other resources – complete with hours of operation, distance from the user, and any special requirements such as training. It also provides a one-click call option on mobile devices. The portal includes information for commercial and public sites and resources, including all standalone pharmacies and pharmacies within larger stores.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |